@Mtnjack68@d_stock07734 IBRX Soon: FACE/mastermind
& blueprint of how to outflank end-run BP/FDA coziness
NBCLA needed the NWBO version of Soon, not a PPT
LG cultivated twitter PR strategy
& during COVID, Podcasts + YouTube became legitimized
& MGMT zzzz
I have beaucoup contacts too
Comms are weak
The Deadliest Brain Cancer Has No Cure—a New Approach May Change That - Newsweek #dcvaxL#atlDC $NWBO. The marketing powerhouse that is mRNA. Meanwhile northwest bio hired an IT guy who lives in LP’s neighborhood. https://t.co/dpacvDgTop
@fine_ole KSA RA: strategic partnership
INFINITE FINANCING
14 cancers notjust GBM
& other applications (autoimm?
vs
UK/USA: disrespected bc full-nelson BP-FDA-UNIV-MEDIA(AF) rubric=caged
$ broke
RFKJ MAHA & still lost
=FRIGHTENED by the ex VIVO DENDRIITIC dcvax ramifications
KSA BOLD
@fine_ole The Saudi Arabian news is better than most news. I don’t think there’s a correlation. I do think I’m at the market makers. Will continue to do whatever they have been doing to make it seem like it’s standard practice.
Some were saying the Dr. Linda Liau said $NWBO needs to conduct a new clinical trial to apply for #DCVax-L FDA approval. That is wrong. She said you can’t use retrospective data to apply for FDA approval. NWBio used prospective data not retrospective: https://t.co/aQ00689UcV
$NWBO $IBRX
$IBRX was $1.98 on 12/31/25.
It hit $12.43 on 2/25/26
The stock first jumped in January after the company got Saudi approvals and is selling its cancer drug.
Saudi drug approvals are real wins for biotech - they open a new market and boost investor confidence as Saudi Arabia builds its biotech industry.
NWBO’s new non-binding MOU with SPIMACO is an early step toward possibly getting that kind of approval and selling DCVax-L there.
@MHRAgovuk@UCLA@bruin_mds